J&J to buy Intra-Cellular for $132/share in cash
by
Contributor since / Followers
Contributor since / Followers
3 months ago
Sundry Photography/iStock Editorial via Getty Images
Johnson & Johnson (NYSE:JNJ) has agreed to acquire all outstanding shares of biopharmaceutical company Intra-Cellular Therapies (NASDAQ:ITCI) for $132.00 a share in cash for a total equity value of around $14.6B.
Shares of Intra-Cellular Therapies (NASDAQ:ITCI), which is focused on